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Abstract Multiple sclerosis (MS) progression to mortal-
ity may not be solely determined by the underlying
autoimmune process. We conducted a study in a large
cohort of MS patients with the aim of describing charac-
teristics of MS patients and identification of predictors for
all-cause mortality in this patient group. We performed a
retrospective analysis of primary care data from the UK
Clinical Practice Research Datalink. Incident MS cases
diagnosed between 1993 and 2006 were identified and
validated using electronic and original medical records.
Patients were followed to identify deaths; hazard ratios
(HRs) and 95 % confidence intervals (CIs) were estimated
using Cox proportional regression with age as time-scale.
In total, 1713 incident MS cases were identified. Following
MS diagnosis, frequent comorbidities were infections
(80 %), and depression (46 %). Adjusted HRs (95 % CIs)
for all-cause mortality were: 2.0 (1.2–3.4) for current
smoking; 7.6 (3.2–17.7) for alcohol abuse; 2.7 (1.6–4.5) for
pneumonia and influenza; 4.1 (2.7–6.3) for urinary tract
infections; 2.2 (1.2–4.2) for heart disease and 4.9 (2.9–8.0)
for cancer. Our results suggest that MS survival is influ-
enced not only by the underlying autoimmune process, but
also by patient comorbidities and lifestyle factors.
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Introduction
Multiple sclerosis (MS) is the most prevalent disabling
neurological disease among young adults [1]. Despite
recent advancements in the understanding of this condition,
many aspects of its aetiological mechanisms remain poorly
understood. Understanding the aetiology and clinical onset
of MS is of increasing importance as evidence suggests an
almost universal increase in the incidence and prevalence
of the disease over the last five decades [1, 2]. An impor-
tant question is whether risk factors and comorbidities for
the disease interact with the underlying autoimmune pro-
cess, or the drugs used to treat it, and the extent that this
may influence mortality. We previously reported on the
results of a study that compared risk factors for and rates of
mortality in MS patients with non-MS patients using a
large, validated UK primary care database [3]. The risk of
mortality was found to be increased in MS compared to
non-MS patients and MS patients had more comorbidities
and co-medications than non-MS patients. Using the same
database we now aim to describe predictors of all-cause
mortality in MS patients only, to better understand the
interaction between the autoimmune process and comor-
bidities. We hypothesised that factors other than the
underlying autoimmune process play an important role in
determining survival in MS patients.
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We conducted a population-based observational study
using data from the UK’s Clinical Practice Research
Datalink (CPRD), formerly the General Practice Research
Database (GPRD). The CPRD contains prospectively
collected data on all aspects of medical care for around 8
million people in the UK. Validation studies have shown
the quality of the CPRD data, which have been used for
several MS studies [3–10], to be generally high [11–14].
Also available are paper records that describe referrals,
hospitalizations and other relevant medical history, often
covering the patient from a young age. These provide an
ideal resource to validate MS diagnoses and determine
dates of MS onset. Details of the database have been
described elsewhere [11–14]. This study was reviewed and
approved by the Independent Scientific Advisory Com-
mittee for UK Medicines and Healthcare products Regu-
latory Agency database research.
Case definition
We identified all patients in the CPRD who had a first
diagnosis code (Online Resource 1) for MS between 1st
January 2001 and 31st December 2006 who had at least
2 years of information in their electronic records. Cases
were identified only through 2006 to provide sufficient
follow-up to develop new outcomes, since the primary
objective of this research was to study the prognosis of
people with MS. Among all potential cases we classified
each according to the likelihood that the MS diagnosis
was valid according to the 2005 revisions to the
McDonald MS criteria where data were available [3, 15].
This process resulted in a series of cases validated through
detailed paper and electronic records, or electronic records
only. For patients with paper records, we were able to get
additional information on the type of MS [relapsing–
remitting MS (RRMS), primary progressive MS (PPMS),
secondary progressive MS (SPMS), and unknown type]
and the presence of MS symptoms at onset. We classified
symptoms, where available, into four main groups: sen-
sory, motor, optic neuritis, and other symptoms (including
other optic and visual anomalies, other cranial nerve
anomalies, dysarthria, and asthenia). For those with no
symptoms recorded, we treated them as a separate group
with missing symptoms. In addition, all incident and
prevalent MS cases still present in the 2012 data update,
identified and validated in our earlier studies conducted
using the GPRD (1993 and 2000) [5–10] were added to
this 2001–2006 case set. Further details of the study
design and validation process have been published previ-
ously [3].
Covariates
Information on the following covariates was extracted from
the database: age at first MS diagnosis, sex, and lifestyle
factors closest to and before the first MS diagnosis including
smoking, body mass index and alcohol abuse (Table 1).
Information on acute infections (recorded on or after first
MS diagnosis), chronic comorbidities (recorded at any time
in the database), and MS treatment (recorded on or after first
MS diagnosis) were also extracted. Comorbidities and MS
treatment evaluated are listed in Table 2. MS treatment
included disease-modifying medications (interferons,
glatiramer acetate, mitoxantrone, and natalizumab), ster-
oids, and symptomatic management drugs (tizanidine,
baclofen, amantadine HCL, modafinil, and fampridine). We
were unable to obtain complete information on use of dis-
ease-modifying medications because, in the UK, they are
generally prescribed in secondary care and are not always
captured in general practice (GP) records.
Statistical analysis
Patient characteristics were described and predictive fac-
tors for all-cause mortality were first identified by calcu-
lating crude hazard ratios (HRs) with 95 % confidence
intervals (CIs) using univariate Cox proportional regression
analyses. Because death was the outcome of interest,
information on acute infections closest to the time of death
was captured. We identified the last instances of each of the
acute infections before end of follow-up and used that
event date to divide follow-up time into two periods: one
not exposed to acute infection and one exposed to acute
infection. If chronic comorbidities were recorded on or
before the first MS diagnosis, follow-up time was treated as
exposed to chronic comorbidities. If chronic comorbidities
developed during follow-up, we used the first event date to
divide follow-up time into two periods: one not exposed to
chronic comorbidities and one exposed to chronic comor-
bidities. MS treatment was treated as time-varying in the
Cox regression models where total follow-up time was
divided into one-year periods and we identified whether
these medications were prescribed at least once in each
period. Given that age is a known risk factor for mortality
and also an important confounder of the associations
between the studied chronic comorbidities (such as heart
disease, cancer, etc.) and mortality, we used age as the
time-scale in the Cox regression models, where patients
entered the analysis at the age at first diagnosis of MS and
exited at their death or censoring age, whichever was
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earlier. We also estimated the adjusted HRs and 95 % CIs
for each predictive factor in the Cox proportional models
which included all predictive factors as well as year of
birth. Because the proportional hazards assumption may
not be met across age, we divided the data into one-year
age strata for each MS patient and fit models separately
within each age stratum. Since age is the time scale, these
age strata refer to attained age, rather than to age at cohort
entry. All analyses were conducted using SAS version 9.3
(SAS Institute, Cary, NC).
Results
Case validation and selection
We identified 1879 people with a first diagnosis of MS
between January 2001 and December 2006. Of these, 998
(53.1 %) had available paper records. These 998 MS cases
were reviewed by a neurologist (G.J.F). Of these, 683
(69 %) were considered to have MS, 87 (9 %) as possible
MS and the remaining 228 (23 %) as not MS, yielding a
Table 1 Basic characteristics
of incident MS cases at MS
diagnosis, stratified by status:
alive/dead
Alive N = 1598
n (%)
Dead N = 115
n (%)
Overall
N = 1713 n (%)
Mean age in years (SD) 41.1 (11.2) 51.4 (14.5) 41.8 (11.7)
Year of birth
\1940 55 (3.4) 32 (27.8) 87 (5.1)
1940–1949 252 (15.8) 30 (26.1) 282 (16.5)
1950–1959 423 (26.5) 26 (22.6) 449 (26.2)
1960–1969 493 (30.9) 21 (18.3) 514 (30.0)
1970? 375 (23.5) 6 (5.2) 381 (22.2)
Sex
Female 1181 (73.9) 79 (68.7) 1260 (73.6)
Male 417 (26.1) 36 (31.3) 453 (26.4)
Smoking status
Never 715 (44.7) 31 (27.0) 746 (43.6)
Current 501 (31.4) 42 (36.5) 543 (31.7)
Former 187 (11.7) 21 (18.3) 208 (12.1)
Unknown 195 (12.2) 21 (18.3) 216 (12.6)
BMI (kg/m2)
\18.5 38 (2.4) 4 (3.5) 42 (2.5)
18.5–24.99 615 (38.5) 47 (40.9) 662 (38.7)
25.0–29.99 372 (23.3) 26 (22.6) 398 (23.2)
C30 229 (14.3) 13 (11.3) 242 (14.1)
Unknown 344 (21.5) 25 (21.7) 369 (21.5)
Alcohol abuse 17 (1.1) 8 (7.0) 25 (1.5)
Type of MSa
RRMS 631 (78.7) 24 (49.0) 655 (77.0)
PPMS 108 (13.5) 10 (20.4) 118 (13.9)
SPMS 49 (6.1) 10 (20.4) 59 (6.9)
Unknown 14 (1.7) 5 (10.2) 19 (2.2)
Symptoms at onseta
Sensory 241 (30.0) 6 (12.2) 247 (29.0)
Motor 186 (23.2) 15 (30.6) 201 (23.6)
Optic neuritis 164 (20.4) 7 (14.3) 171 (20.1)
Multiple symptomsb 42 (5.2) 7 (14.3) 49 (5.8)
Other 98 (12.2) 5 (10.2) 103 (12.1)
Missing 71 (8.9) 9 (18.4) 80 (9.4)
BMI body mass index, MS multiple sclerosis, PPMS primary progressive MS, RRMS relapsing-remitting
MS, SD standard deviation
a Among 851 MS cases confirmed by original records (1993–2006)
b 49 MS patients had multiple symptoms at onset
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positive predictive value of 68 % (95 % CI 65.5–71.3). Out
of 881 cases with unavailable paper records, validation
based solely on electronic records yielded 429 probable
and 229 possible MS cases (658 cases in total). Altogether
1278 incident and 63 prevalent MS cases were identified
from 2001 to 2006 (Fig. 1 for MS validation process). In
addition, 435 incident and 46 prevalent MS cases identified
between 1993 and 2000 who were still present in the cur-
rent database were retrieved from previous studies [5–10],
giving a total of 1822 MS cases (1507 definite or probable
and 315 possible) including 1713 incident and 109 preva-
lent MS cases (Fig. 1). Because reliable information on MS
Table 2 Comorbidities and MS medications among incident MS cases, stratified by status: alive/dead
Alive N = 1598 n (%) Dead N = 115 n (%) Overall N = 1713 n (%)
Acute infections recorded on or after first MS diagnosis
Pneumonia and influenza 112 (7.0) 29 (25.2) 141 (8.2)
Other acute respiratory infection 751 (47.0) 53 (46.1) 804 (46.9)
Urinary tract infection 495 (31.0) 60 (52.2) 555 (32.4)
Other infection 1063 (66.5) 62 (53.9) 1125 (65.7)
Chronic comorbidities recorded at any time in the database
COPD and asthma 315 (19.7) 28 (24.3) 343 (20.0)
Depression 730 (45.7) 55 (47.8) 785 (45.8)
Diabetes 79 (4.9) 14 (12.2) 93 (5.4)
Hypertension 232 (14.5) 21 (18.3) 253 (14.8)
Heart diseasea 48 (3.0) 18 (15.7) 66 (3.9)
Cancer 83 (5.2) 26 (22.6) 109 (6.4)
Co-medications recorded on or after first MS diagnosis
MS treatmentb 1028 (64.3) 85 (73.9) 1113 (65.0)
COPD chronic obstructive pulmonary disease, MS multiple sclerosis
a Includes ischemic heart disease, angina, myocardial infarction, and heart failure
b Includes disease-modifying medications (interferons, glatiramer acetate, mitoxantrone, and natalizumab), steroids, and symptomatic man-
agement drugs (tizanidine, baclofen, amantadine HCL, modafinil, and fampridine)
Fig. 1 Selection of study sample
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type and symptoms at onset was only available for incident
cases, we restricted the study analyses to the 1713 incident
MS cases.
Patient characteristics
Sixty per cent of the 1713 incident MS cases were first
diagnosed between ages 30 and 49 (data not shown); mean
42 years, and a majority were female (74 %). Current or
former smoking and alcohol abuse were more prevalent
among the MS patients who died during follow-up than
those who did not die (p\ 0.01 for all). Among patients
whose diagnosis was made based on original clinical
records (n = 851), 77 % had RRMS, 14 % had PPMS,
7 % had SPMS and 2 % had an unknown subtype; sensory,
motor symptoms, and optic neuritis were the most common
symptoms recorded at MS diagnosis (Table 1 shows fur-
ther data on characteristics of the patient population at first
MS diagnosis).
MS patients had a high prevalence of several con-
comitant conditions and MS treatment (Table 2). Infections
were the most frequently recorded acute comorbidity on or
after first MS diagnosis, occurring in 80 % of patients.
Depression, recorded at any time in the database, was the
most frequently recorded chronic comorbidity, occurring in
46 % of patients. Prevalence was higher in MS patients
who died during follow-up than those who did not die: 25
vs. 7 %, p\ 0.0001 for pneumonia and influenza; 52 vs.
31 %, p\ 0.0001 for urinary tract infection; 12 vs. 5 %,
p = 0.0009 for diabetes; 16 vs. 3.0 %, p\ 0.0001 for heart
disease; and 23 vs. 5 %, p\ 0.0001 for cancer.
Risk factors for all-cause mortality
A total of 115 (6.7 %) MS patients died during 13,573
person-years of follow-up. The mean age at first MS diag-
nosis was higher in patients who died (51.4) than those who
did not die during study follow-up (41.1). Mean age at death
was 56.9. Current and former smokers at the time of diag-
nosis had increased risks of death (adjusted HR 2.0, 95 %
CI 1.2–3.4; and adjusted HR 2.5, 95 % CI 1.3–4.5, sepa-
rately), as well as patients with a history of alcohol abuse at
the time of diagnosis (adjusted HR 7.6, 95 % CI 3.2–17.7).
Among MS cases confirmed by original clinical records,
patients with PPMS had a higher risk of death compared
with patients with RRMS (adjusted HR 2.2, 95 % CI
0.9–5.5), although it was borderline statistically significant.
Compared with patients with sensory symptoms only,
patients with other types of symptoms had increased risks of
death, particularly patients with multiple symptoms at onset
who had a greatly increased risk (adjusted HR 9.0, 95 % CI
2.2–36.3). These effects were based on the 851 MS cases
who had paper records and, therefore, details of first
symptoms. We only had data on symptoms for 49 MS
patients who died. Thus, this effect was based on a small
number of cases, never-the-less, the finding was robust and
was stronger when covariates were added to the model; see
Table 3 for details. Several comorbidities were found to be
significant predictors of death; adjusted HRs (95 % CIs)
were: 2.7 (1.6–4.5) for pneumonia and influenza, 4.1
(2.7–6.3) for urinary tract infections, 2.2 (1.2–4.2) for heart
disease, and 4.9 (2.9–8.0) for cancer. MS treatment was
associated with a reduced risk of death in these data (ad-
justed HR 0.6, 95 % CI 0.4–1.0). See Table 4.
Discussion
This large, population-based study of 1713 people with
incident MS in UK primary care provides important data
on the clinical characteristics of this patient population
including prognostic factors for mortality. We observed
that MS patients suffer from various conditions, with
infections and depression the most common, but we also
identified several other important predictors for all-cause
mortality among MS patients, including smoking, alcohol
abuse, multiple symptoms at first diagnosis, pneumonia and
influenza, urinary tract infection, heart disease, and cancer.
Others have similarly found that people with multiple
comorbidities had an increased risk of mortality [16], and
that cardiovascular disease and respiratory infections were
associated with higher mortality in MS patients [17–19]. A
history of urinary tract infections was also found to be
associated with decreased survival in these data; however,
these observations are likely to reflect MS severity rather
than a causal association. Sex was not associated with
mortality in this study. The effect of sex has been shown to
vary greatly across studies, over time, and between coun-
tries [16–18].
An important objective of this study was to explore
whether risk factors and comorbidities for MS interact with
the underlying autoimmune process, or the drugs used to
treat it, and the extent that these may influence mortality.
As expected, we found that people with MS were at high
risk of infections of all kinds possibly in part due to the use
of immunosuppressant drug treatment. The strong associ-
ation between pneumonia and risk of mortality could
reflect the high risk of pneumonia infection in the MS
population in concert with the high risk of death among
those who develop pneumonia. We also found that patients
who received MS treatments had a reduced risk of death;
however, we cannot separate the effects of the drug from
the effects of the comorbidities.
Patients who had infections and chronic comorbidities
were often found to die of that underlying disease. Among
the 29 MS patients who died and who had a history of
J Neurol (2015) 262:2033–2041 2037
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pneumonia, the pneumonia was considered to be at least
one of the causes of death in 22 (76 %) instances. Note that
cause of death was not available for all patients who died
and pneumonia may have been the cause of death for
additional MS patients. This supports the notion that if
patients have MS and develop pneumonia, the risk of death
is high and perhaps higher than in the general population.
Cancer was the known cause of death for 21 (81 %) of 26
MS patients who ever had a diagnosis of cancer in their
record and subsequently died. Among the 18 MS patients
who had a history of heart disease and died, 13 (72 %) died
of cardiovascular disease. In all, 11 of the 115 MS patients
who died had MS as the only listed cause of death.
We found that patients with multiple symptoms at MS
onset had an increased risk of death compared with those
with only sensory symptoms, among cases whose diagnosis
was confirmed from their original clinical records during
1993–2006. In a large Finnish cohort of MS patients,
Sumelahti et al. [18] reported that optic neuritis or other
sensory symptoms at presentation were associated with
Table 3 Risk of all-cause
mortality among incident MS
patients
Characteristic Crude HR (95 % CI) p value Adjusted HRa (95 % CI) p value
Sex




Current 2.7 (1.7–4.3) \0.0001 2.0 (1.2–3.4) 0.006
Former 2.4 (1.4–4.3) 0.002 2.5 (1.3–4.5) 0.004
Unknown 2.4 (1.3–4.3) 0.003 2.5 (1.3–5.0) 0.007
BMI (kg/m2)
\18.5 2.2 (0.8–6.0) 0.1 1.6 (0.5–5.0) 0.4
18.5–24.99 Reference Reference
25.0–29.99 0.8 (0.5–1.4) 0.5 0.8 (0.5–1.4) 0.4
C30 0.9 (0.5–1.7) 0.7 0.9 (0.5–1.9) 0.8
Unknown 1.0 (0.6–1.6) 0.9 0.9 (0.5–1.6) 0.7
Alcohol abuse 7.5 (3.6–15.7) \0.0001 7.6 (3.2–17.7) \0.0001
Type of MSb
RRMS Reference Reference
PPMS 1.7 (0.8–3.6) 0.2 2.2 (0.9–5.5)c 0.1
SPMS 3.3 (1.5–6.9) \0.0001 1.7 (0.6–4.6)c 0.3
Unknown 3.2 (0.8–12.5) 0.09 7.7 (1.8–33.3)c 0.007
Symptoms at onsetb
Sensory Reference Reference
Motor 2.7 (1.0–7.0) 0.04 5.8 (1.8–18.1)e 0.003
Optic neuritis 1.8 (0.6–5.4) 0.3 4.0 (1.1–14.6)e 0.04
Multiple symptomsd 3.6 (1.2–10.8) 0.02 9.0 (2.2–36.3)e 0.002
Other 2.0 (0.6–6.6) 0.2 5.2 (1.2–21.4)e 0.02
Missing 2.9 (0.9–9.2) 0.08 11.3 (2.9–43.4)e 0.0004
BMI body mass index, CI confidence interval, HR hazard ratio, MS multiple sclerosis, PPMS primary
progressive MS, RRMS relapsing-remitting MS
a Estimates of HRs were obtained in a Cox regression model including sex, year of birth, smoking status,
body mass index, a history of alcohol use, acute infection, chronic comorbidities, and MS treatment
b Among 851 MS cases confirmed by original records (1993–2006)
c Estimates of HRs were obtained in a Cox regression model including sex, year of birth, smoking status,
body mass index, a history of alcohol use, acute infection, chronic comorbidities, MS treatment, and type of
MS
d 49 MS patients with multiple different symptoms at onset
e Estimates of HRs were obtained in a Cox regression model including sex, year of birth, smoking status,
body mass index, a history of alcohol use, acute infection, chronic comorbidities, MS treatment, and
symptoms at onset
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favourable survival. To the best of our knowledge, the
association with multiple symptoms found in this study is
new and should be investigated further.
Patients in this study with PPMS compared to RRMS
were at increased risk for mortality (adjusted HR 2.2),
although it was borderline significant. There were too few
people with SPMS (adjusted HR 1.7) to obtain a reliable
risk estimate. Compared with other existing studies [16–
19], our follow-up was relatively short which could explain
the small number of cases, though, since these forms of MS
are more severe the higher risk was expected. The average
length of follow-up from first MS diagnosis was 7.7 years
in our study. The highest HR, however, was found among
people with unknown MS type. First, this result was based
on a small number of patients and is thus not stable. Sec-
ond, we were less likely to obtain original clinical records
for patients who had died, so this group of MS patients is
not a random sample of all MS patients but may represent
patients with more severe types of MS, which could
explain the strong association with risk of mortality.
We found that more patients died from cancer than from
heart disease in this study. Since most MS patients in this
study were female, this finding mainly reflects cause of
death in women where CVD is not a major cause until after
menopause. It is noteworthy that more men died from CVD
than from cancer in this study. Since the mean age of death
in this study was around 57, this finding is consistent with
the leading causes of deaths in White women of the same
age [20]. The limited follow-up time in this study pre-
cluded following people until later age when mortality
rates are higher. An alternative explanation is that MS
patients could have better control of vascular risk factors
compared to the general population. This could be the
result of the close medical monitoring received by these
patients and the fact that, confronted with a chronic and
incurable disease, physicians will strive to correct those
comorbidities amenable to treatment in an effort to
decrease the total morbidity burden of their patients.
Finally, it is also possible that the autoimmune process
underlying MS, or the immunomodulatory agents used to
treat it, or a combination of both, results in a slower pro-
gression of the atherosclerotic process that leads to heart
disease.
Another relevant finding of the present study is the
association between the infectious processes and mortality
in MS patients. It is indeed feasible that this is a spurious
association, possibly due to confounding generated by un-
or incompletely measured factors associated with both
infection occurrence and death. One obvious candidate for
this inadequately controlled confounding is treatment for
MS, for which we did not have complete information.
Therapeutic strategies to confront MS involve modulating
the immune system and could thus be related to the inci-
dence and prevalence of infections via decreased
Table 4 Comorbidities and MS medications and risk of all-cause mortality among incident MS patients
Model 1 Model 2
Crude HR (95 % CI) p value Adjusted HRa (95 % CI) p value
Acute infectionsb
Pneumonia and influenza 4.8 (3.1–7.5) \0.0001 2.7 (1.6–4.5) 0.0001
Other acute respiratory infection 2.2 (1.5–3.3) \0.0001 1.3 (0.8–2.0) 0.2
Urinary tract infection 4.8 (3.3–7.1) \0.0001 4.1 (2.7–6.3) \0.0001
Other infection 2.6 (1.8–3.8) \0.0001 1.7 (1.1–2.6) 0.02
Chronic comorbiditiesb
COPD and asthma 1.4 (0.9–2.2) 0.1 1.0 (0.6–1.6) 0.9
Depression 1.4 (1.0–2.1) 0.06 1.0 (0.7–1.5) 1.0
Diabetes 2.4 (1.3–4.3) 0.003 1.2 (0.6–2.5) 0.6
Hypertension 0.9 (0.5–1.4) 0.6 0.7 (0.4–1.2) 0.2
Heart disease 3.1 (1.8–5.3) \0.0001 2.2 (1.2–4.2) 0.01
Cancer 5.5 (3.4–8.6) \0.0001 4.9 (2.9–8.0) \0.0001
Comedicationsb
MS treatmentc 0.6 (0.4–1.0) 0.03 0.6 (0.4–1.0) 0.05
COPD chronic obstructive pulmonary disease, CI confidence interval, HR hazard ratio, MS multiple sclerosis
a Estimates of HRs were obtained in a Cox regression model including sex, year of birth, smoking status, body mass index, a history of alcohol
use, acute infection, chronic comorbidities, and MS treatment
b Time-varying variables
c Includes disease-modifying medications (interferons, glatiramer acetate, mitoxantrone, and natalizumab), steroids, and symptomatic man-
agement drugs (tizanidine, baclofen, amantadine HCL, modafinil, and fampridine)
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immunity, and to mortality via either adverse reactions or
disease severity. However, the observation that infections
represent a common cause of death in other chronic con-
ditions like Parkinson’s disease [21] suggests that the
described statistical association between infection and
mortality could also represent a true biological phe-
nomenon. One causal structure that could account for the
described association involves the relationship between
infections and treatment in terms of mediation rather than
confounding: MS immunomodulatory therapies predispose
MS patients to suffer infections, which in turn cause death.
Strengths of our study include the large sample size and
high quality database. In addition, our findings are gener-
alizable to the UK population as a whole because of the
representative population-based nature of the CPRD.
Additionally, we were able to validate MS diagnoses by
accessing original patient clinical records for a large pro-
portion of cases, which, along with linkage to death reg-
istry data, enabled additional clinical information to be
obtained. Finally, we used age as the time-scale in the Cox
proportional regression models instead of time-on-study,
the scale used in most previously reported MS studies, to
better estimate the effects of predictive factors for death
controlling for age. Moreover, because patients may have
developed MS many months or years prior to their first MS
diagnosis, if we had estimated mortality where we followed
patients from the first MS diagnosis, left truncation would
have been present in this study. Using age as the time scale
accounted for the left truncation issue [22] and is more
appropriate in this study.
We were, however, unable to validate the MS diagnosis
via original records for all patients; thus, it is likely that
some misclassification occurred. Any misclassification
would likely have been random, non-differential, and any
effects on the HRs would likely have been small and
biased towards the null. We were also unable to describe
the patient population regarding vitamin D status or eth-
nicity as this information is not systematically recorded by
GPs. While it is thought that vitamin D deficiency is
associated with the risk of cancer [23] and cardiovascular
diseases [24], the magnitude of these associations is not
strong; thus, the absence of information is unlikely to
materially impact the results of this study. Recent popu-
lation-based studies have also reported significant differ-
ences in the incidence of MS across ethnic groups. Since
the vast majority of people in the UK are Caucasian it is
unlikely that the inability to control for ethnicity would
materially alter the results. Additionally, we were unable
to evaluate the influence of the different MS treatments,
particularly interferon beta which has been shown to slow
disease progression [25, 26] and reduce all-cause mortality
[27, 28] in patients with RRMS. Because in the UK, it is
mostly prescribed in secondary care and not always
captured in GP records, there were very few MS patients
in this study who had records for interferon beta. This
may have affected the estimates of all-cause mortality
among RRMS patients in our study, yet is unlikely to have
affected the HRs associated with the observed predictive
factors for all-cause mortality. Finally, we did not have
information on socioeconomic status (SES) for patients in
this study, so we could not evaluate its effect on mortality.
Since all people in the UK are covered by the National
Health Service, access to medical care due to SES should
not have had a major effect on MS care. However, we still
cannot rule out the possibility that our results are con-
founded by SES.
In conclusion, our population-based study suggests that
several factors, some of which are modifiable, act in
combination with the autoimmune process responsible for
the clinical manifestation of MS. Smoking, alcohol abuse,
pneumonia and influenza, urinary tract infections, heart
disease and cancer were all predictive factors of reduced
survival among this patient group. Further work is war-
ranted to evaluate how these factors compare with those in
the general population.
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